Aberrant epigenetic regulation is a central driver of tumorigenesis, and the reversibility of epigenetic modifications underscores their potential as therapeutic targets. Epigenetic factors often function in a highly context-dependent manner, necessitating rigorous study of their dynamic and complex roles. Here, we unc...
Laura Leonhardt, Jia-Zhuan Mei, Audrey M. Hendley et al.· Cancer Research· 0 citations
BACKGROUND AND AIMS
Extrahepatic organ failures are key determinants of acute-on-chronic liver failure (ACLF). While the role of systemic inflammation and mitochondrial dysfunction in the pathogenesis of ACLF is well known, the contribution of the liver itself is less understood. We therefore performed transcriptome an...
Mona-May Langer, H. Stadler, M. Mannewitz et al.· JHEP Reports· 0 citations
Prostate-specific membrane antigen (PSMA)-targeted α-therapy holds promise for the treatment of prostate cancer but has increased side effects compared with therapy using β-emitting PSMA ligands. This emphasizes the need for precise imaging of the biodistribution of 225Ac-labeled ligands for patient selection and dosim...
Bai-Qing Sun, Daniel Werner, Jun-Cheng Ni et al.· Journal of Nuclear Medicine· 0 citations
ABSTRACT Direct in vivo characterization of the interplay between tumor hypoxia, acidosis, and metabolic reprogramming remains a major translational challenge. Here, we establish a clinically deployable simultaneous PET/MRI workflow on a clinical 3 T system that combines hyperpolarized 13C MRI of [1‐13C]pyruvate to map...
Martin Grashei, Tanja Groll, S. Kahl et al.· Advancement of science· 0 citations
It is demonstrated for the first time that LOY is significantly enriched in advanced-stage disease and the aggressive basal molecular subtype, establishing LOY as a causal genetic driver of PDAC progression, acting through epigenetic remodeling to promote EMT, basal subtype identity, metastasis, and therapy resistance.
M. Dorsch, Felix E. G. Beaudry, A. Baginska et al.· Cancer Research· 0 citations
Anti-CD40L treatment may be an effective intervention to mitigate progressive immunopathology associated with meningeal TLS, and modulates and likely silences other CD40-dependent antigen-presenting cells in the CNS, including myeloid cells and astrocyte subsets.
Sofia Tyystjärvi, Diego Ruiz Navarro, Leni-Mihaela Kulisch et al.· Brain : a journal of neurolo...· 0 citations
A single-cell multiomics atlas of the human pancreas is presented, profiling over four million cells and nuclei from 57 donors across fetal development, adult homeostasis, and type 2 diabetes.
E. Mereu, D. Balboa, J. Liebig et al.· Cell Metabolism· 1 citation
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.